Abstract
During the latter part of the twentieth century, substantial improvements were made in the treatment of childhood cancers. Fifty years ago, most pediatric cancers were fatal. Today, however, more than 75% of pediatric patients with cancer survive the disease. Most advances have been achieved through extensive research and well-designed clinical trials. Investigators continue to explore novel therapies with the goals of providing salvage treatment to patients whose disease does not respond to current therapies and of improving the efficacy and safety of frontline regimens. Recent advances in the fields of genetics, immunology, and molecular biology have led to a better understanding of childhood cancers, which in turn has led to the rational design of drugs based on a thorough understanding of targets on or inside malignant cells. Such an approach aims to further improve cure rates and reduce toxicity. This chapter describes the novel therapies available to pediatric patients at M. D. Anderson Cancer Center. We describe the difficulties of conducting innovative research in children as well as how multidisciplinary interactions at M. D. Anderson help children quickly and safely benefit from novel therapies, including stem cell transplantation for leukemia, lymphoma, and other solid tumors.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Aleksa K, Koren G. Ethical issues in including pediatric cancer patients in drug development trials. Paediatr Drugs 2002;4:257–265.
Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 2003;31:459–465.
Couriel DR, Hicks K, Giralt S, et al. Phase III trial with infliximab/ methylprednisolone (MP) vs (MP) for the treatment of acute GVHD: preliminary findings. Biol Blood Marrow Transplant 2003a;9:95.
Couriel DR, Hicks K, Saliba R, et al. Sirolimus (Rapamycin) for treatment of steroid-refractory chronic graft versus host disease. Biol Blood Marrow Transplant 2003b;9:67.
Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol 2003;25:584–588.
Jeha S, Gandhi V, Chan KW, et al. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2004;103:784–789.
Kleinerman ES. Biological therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 1995;9:927–938.
Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrowtransplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165–1173.
Nahata MC. Need for conducting research on medications unlabeled for use in pediatric patients. Ann Pharmacother 1994;9:1103–1104.
Przepiorka D, Blamble D, Hilsenbeck S, et al. Tacrolimus clearance is agedependent within the pediatric population. Bone Marrow Transplant 2002;26:601–605.
Reaman GH. Pediatric oncology: current views and outcomes. Pediatr Clin North Am 2002;6:1305–1318.
Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric drug labeling. JAMA 2003;290:905–911.
Sleight B, Chan K, Serrano A, et al. Infliximab for GVHD therapy in children. Biol Blood Marrow Transplant 2003;9:96.
Somberg JC. Pediatric drug development. Am J Ther 2003;10:2.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Jeha, S.S., Worth, L.L. (2005). Novel Therapeutic Approaches. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-24472-3_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24470-9
Online ISBN: 978-0-387-24472-3
eBook Packages: MedicineMedicine (R0)